Apremilast
Otezla
Phosphodiesterase 4 Inhibitor
NADAC/unit
$89.9522
No Shortage
Tier 1: 85.7%
PA Req: 447.4%
5 Manufacturers
15 ANDAs
OTEZLA/OTEZLA XR, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with: Active psoriatic arthritis ( 1.1 ) Plaque psoriasis who are candidates for phot....
vs. brand Otezla: Generic saves up to -800% per unit
Generic Manufacturers
ALKEM LABORATORIES LTDAMGEN INCANNORA PHARMA PRIVATE LTDMANKIND PHARMA LTDMSN LABORATORIES PRIVATE LTDSHILPA MEDICARE LTD
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.